Boehringer invests $50m in Click Therapeutics Series D
The investment accompanies the transfer of CT-155 commercialization responsibilities to Click.
Boehringer Ingelheim made a $50 million Series D investment in Click Therapeutics under an agreement announced on April 9. It also provided dedicated commercial funding, whose value was not disclosed.
The agreement transfers full product responsibility for CT-155, including commercial and marketing authorization rights, to Click. Boehringer will continue to lead completion of the ENSPIRUS study.
Click subsequently announced FDA clearance for CT-155, branded Motivista, on October 5. The company was preparing the prescription digital treatment for broader commercial availability.
Use of funds
Commercialize CT-155 as Click takes over product and marketing responsibilities.